IDNA Genomics Public Ltd (CYS:IDNA)
Cyprus flag Cyprus · Delayed Price · Currency is EUR
28.20
0.00 (0.00%)
At close: Aug 7, 2025

IDNA Genomics Public Income Statement

Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023
Period Ending
Dec '24 Dec '23
0.480.49
Revenue Growth (YoY)
-3.01%-
Cost of Revenue
0.350.17
Gross Profit
0.130.32
Selling, General & Admin
1.671.54
Other Operating Expenses
-0.07-0.01
Operating Expenses
1.611.53
Operating Income
-1.48-1.2
Interest Expense
-0.15-0.13
Other Non Operating Income (Expenses)
-0-0
EBT Excluding Unusual Items
-1.63-1.34
Impairment of Goodwill
-1.34-
Pretax Income
-2.97-1.34
Income Tax Expense
0.010.01
Earnings From Continuing Operations
-2.97-1.34
Minority Interest in Earnings
0.45-
Net Income
-2.52-1.34
Net Income to Common
-2.52-1.34
Shares Outstanding (Basic)
33
Shares Outstanding (Diluted)
33
EPS (Basic)
-0.91-0.49
EPS (Diluted)
-0.91-0.49
Free Cash Flow
-2.53-0.01
Free Cash Flow Per Share
-0.92-0.01
Gross Margin
27.22%65.56%
Operating Margin
-309.19%-244.23%
Profit Margin
-527.75%-272.77%
Free Cash Flow Margin
-528.51%-2.62%
EBITDA
-1.31-1.12
EBITDA Margin
-274.54%-227.85%
D&A For EBITDA
0.170.08
EBIT
-1.48-1.2
EBIT Margin
--244.23%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.